
-
Germany suspends arms exports to Israel for use in Gaza
-
Stocks waver, gold futures hit record on US tariff updates
-
Guessand says he jumped at chance to join Aston Villa after sealing move
-
Israel to 'take control' of Gaza City, sparking wave of criticism
-
Accumulating bitcoin a risky digital rush by companies?
-
Liverpool's Slot hints at fresh Isak bid despite 'attacking power'
-
PSG to sign Lille goalkeeper Lucas Chevalier: source
-
Oil industry presence surges at UN plastic talks: NGOs
-
Kipyegon says a woman will run a sub-four minute mile
-
Tokyo soars on trade deal relief as most Asian markets limp into weekend
-
Israel to 'take control' of Gaza City after approving new war plan
-
Australian A-League side Western United stripped of licence
-
'Back home': family who fled front buried after Kyiv strike
-
Indonesia cracks down on pirate protest flag
-
Israeli army will 'take control' of Gaza City: PM's office
-
Australian mushroom murderer accused of poisoning husband
-
Coventry's mettle tested by Russian Olympic debate, say former IOC figures
-
Library user borrows rare Chinese artwork, returns fakes: US officials
-
Parisians hot under the collar over A/C in apartments
-
Crypto group reportedly says it planned sex toy tosses at WNBA games
-
American Shelton tops Khachanov to win first ATP Masters title in Toronto
-
Tokyo soars on trade deal relief as Asian markets limp into weekend
-
New species teem in Cambodia's threatened karst
-
Australian mushroom murderer accused of poisoning husband: police
-
Solid gold, royal missives and Nobel noms: how to win Trump over
-
Canadian teen Mboko outlasts Osaka to win WTA Montreal crown
-
Trump to host Armenia, Azerbaijan for historic 'Peace Signing'
-
Israeli airline's Paris offices daubed with red paint, slogans
-
US raises bounty on Venezuela's Maduro to $50 mn
-
Lebanon cabinet meets again on Hezbollah disarmament
-
France's huge wildfire will burn for days: authorities
-
Bolivia right-wing presidential hopeful vows 'radical change'
-
Trump says would meet Putin without Zelensky sit-down
-
Trump offers data to justify firing of labor stats chief
-
Bhatia leads by one at PGA St. Jude, Scheffler five adrift
-
Disney settles Trump-supporting 'Star Wars' actor lawsuit
-
Trump moves to kill $7 billion in solar panel grants
-
Venus Williams falls at first hurdle in Cincinnati
-
Mixed day for global stocks as latest Trump levies take effect
-
SpaceX agrees to take Italian experiments to Mars
-
US judge orders temporary halt to new 'Alligator Alcatraz' construction
-
US uses war rhetoric, Superman to recruit for migrant crackdown
-
US to rewrite its past national climate reports
-
U can't pay this: MC Hammer sued over delinquent car loan
-
WHO says nearly 100,000 struck with cholera in Sudan
-
Huge wildfire in southern France now under control
-
Kane scores as Bayern thump Spurs in pre-season friendly
-
France strikes down return of banned bee-killing pesticide
-
Canada sends troops to eastern province as fire damage grows
-
OpenAI releases ChatGPT-5 as AI race accelerates
SCU | 0% | 12.72 | $ | |
RBGPF | -5.79% | 71.84 | $ | |
CMSD | -0.09% | 23.52 | $ | |
NGG | -0.31% | 72.08 | $ | |
RIO | 1.12% | 60.77 | $ | |
CMSC | 0.04% | 22.96 | $ | |
RYCEF | -0.42% | 14.44 | $ | |
VOD | -0.36% | 11.26 | $ | |
RELX | 1.03% | 49.32 | $ | |
BTI | 0.51% | 56.69 | $ | |
SCS | 0.06% | 16 | $ | |
GSK | 2.21% | 37.58 | $ | |
BCE | 2.23% | 23.78 | $ | |
BCC | 0.32% | 83.19 | $ | |
JRI | 0.52% | 13.41 | $ | |
AZN | 1.3% | 74.57 | $ | |
BP | 0.91% | 34.19 | $ |

Mice trial raises hopes for 'on demand' male contraceptive
If women have the "morning after" pill, could men one day have an "hour before" pill?
A new drug candidate renders male mice infertile within an hour and wears off in less than a day, an experimental study said Tuesday, potentially pointing towards a future "on-demand" male contraceptive.
The potential drug, which has not been tested in humans and remains years away from possibly becoming available, joins a growing number of male contraceptives in development.
However there are currently only two options available for men: condoms and vasectomies.
Previous drugs have struggled partly because the bar for side effects is believed to be far higher for men -- because they do not risk getting pregnant -- as well as a lack of interest from the pharmaceutical industry.
"For women, right now all the burden of contraception is on us," Melanie Balbach, a pharmacology researcher at Weill Cornell Medicine in the US, told AFP.
"We want new options," said Balbach, the lead author of the study published in Nature Communications.
The team of researchers targeted an enzyme called soluble adenylyl cyclase, which acts as the "on switch" for sperm, said study co-author Jochen Buck, also of Weill Cornell Medicine.
If the enzyme is switched off, the sperm can no longer move, he said.
Across several different tests, the researchers showed that a compound which blocks the enzyme renders mice sperm immobile in 30 minutes to an hour.
The compound was 100 percent effective in preventing pregnancy within the first two hours, dropping to 91 percent in the first three hours, the study said.
After 24 hours, the mice sperm moved like normal again.
- 'Eye-catching advantage' -
The researchers hope are aiming for a single non-hormonal pill that works in under an hour and lasts six to 12 hours, Buck said.
This would be much different to other options under development, such as a hormonal gel currently going through human trials, which all take weeks or months to start and stop working.
No side effects were noticed in the mice. Previous research has suggested that infertile men who had their soluble adenylyl cyclase enzyme permanently switched off had an increased rate of kidney stones.
Buck said this was the result of their enzyme always being off -- which would not be the case for men taking an on demand pill.
The researchers hope to hold the first trials on humans within three years, with a final product possibly up to eight years away, Buck said.
Susan Walker, an expert in contraception at the UK's Anglia Ruskin University not involved in the research, said she was a "little sceptical" a pill would actually make it to market as so many other efforts have fallen short.
But the "eye-catching advantage" of almost immediate effectiveness offered "the possibility of seeing a sexual partner take a pill," she said.
The consultancy Desire Line is working on forecasting the potential uptake of a range of male contraceptive products, according to its founder Steve Kretschmer.
"Initial estimates indicate in the United States that uptake for an on-demand pill which has quick onset of action and 1-2 days duration of action could be about triple that of Viagra when it was initially launched," he told AFP.
B.Mahmoud--SF-PST